表紙:婦人科系疾患治療薬の世界市場(2022年~2028年)
市場調査レポート
商品コード
1078037

婦人科系疾患治療薬の世界市場(2022年~2028年)

Global Women Health Therapeutics Market 2022-2028

出版日: | 発行: Orion Market Research | ページ情報: 英文 135 Pages | 納期: 2~3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.76円
婦人科系疾患治療薬の世界市場(2022年~2028年)
出版日: 2022年04月13日
発行: Orion Market Research
ページ情報: 英文 135 Pages
納期: 2~3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の婦人科系疾患治療薬の市場規模は、予測期間中にCAGRで5.3%の大幅な成長が予測されています。市場の成長に寄与している主な要因の1つは、乳がんの負担の増大による、健康診断と治療薬に対する世界的な需要の高まりです。

当レポートでは、世界の婦人科系疾患治療薬市場について調査分析し、市場概要、競合情勢、セグメント分析、地域分析などを提供しています。

目次

第1章 レポートサマリー

第2章 市場概要と考察

  • 調査範囲
  • アナリストの考察と現在の市場動向

第3章 競合情勢

  • 主要企業分析
    • Abbott Laboratories, Inc.
    • Bayer AG
    • Eli Lilly and Co.
    • F. Hoffmann-La Roche LTD.
    • Novartis AG
  • 主要戦略分析
  • 主要企業に対するCOVID-19の影響

第4章 市場セグメンテーション

  • 世界の婦人科系疾患治療薬市場:タイプ別
    • 感染
    • 妊娠
    • 腫瘍
  • 世界の婦人科系疾患治療薬市場:エンドユーザー別
    • 病院・診療所
    • 外来センター

第5章 地域分析

  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • イタリア
    • スペイン
    • フランス
    • その他の欧州
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • その他のアジア太平洋
  • その他の地域

第6章 企業プロファイル

  • Airgas, Ltd.
  • Allergan PLC
  • Amgen Inc.
  • Astellas Pharma Inc.
  • Bayer AG
  • Eli Lilly and Co
  • ICON PLC
  • Merck KGaA
  • Mithra Pharmaceuticals S.A.
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Oasmia Pharmaceutical AB
  • ObsEva SA
  • Radius Health, Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Co. Ltd.
  • Teva Pharmaceuticals Industries Ltd.
  • Tsumura & Co.Arkema S.A.
図表

LIST OF TABLES

  • 1. GLOBAL WOMEN HEALTH THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
  • 2. GLOBAL WOMEN HEALTH THERAPEUTICS FOR INFECTION MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 3. GLOBAL WOMEN HEALTH THERAPEUTICS FOR PREGNANCY MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 4. GLOBAL WOMEN HEALTH THERAPEUTICS FOR ONCOLOGY MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 5. GLOBAL WOMEN HEALTH THERAPEUTIC MARKET RESEARCH AND ANALYSIS BY END-USER, 2021-2028 ($ MILLION)
  • 6. GLOBAL WOMEN HEALTH THERAPEUTICS IN HOSPITALS AND CLINICS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 7. GLOBAL WOMEN HEALTH THERAPEUTICS IN AMBULATORY CENTERS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 8. GLOBAL WOMEN HEALTH THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2021-2028 ($ MILLION)
  • 9. NORTH AMERICAN WOMEN HEALTH THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 10. NORTH AMERICAN WOMEN HEALTH THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
  • 11. NORTH AMERICAN WOMEN HEALTH THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY END-USER, 2021-2028 ($ MILLION)
  • 12. EUROPEAN WOMEN HEALTH THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 13. EUROPEAN WOMEN HEALTH THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
  • 14. EUROPEAN WOMEN HEALTH THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY END-USER, 2021-2028 ($ MILLION)
  • 15. ASIA-PACIFIC WOMEN HEALTH THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 16. ASIA-PACIFIC WOMEN HEALTH THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
  • 17. ASIA-PACIFIC WOMEN HEALTH THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY END-USER, 2021-2028 ($ MILLION)
  • 18. REST OF THE WORLD WOMEN HEALTH THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 19. REST OF THE WORLD WOMEN HEALTH THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
  • 20. REST OF THE WORLD WOMEN HEALTH THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY END-USER, 2021-2028 ($ MILLION)

LIST OF FIGURES

  • 1. IMPACT OF COVID-19 ON GLOBAL WOMEN HEALTH THERAPEUTICS MARKET, 2021-2028 ($ MILLION)
  • 2. IMPACT OF COVID-19 ON GLOBAL WOMEN HEALTH THERAPEUTICS MARKET BY SEGMENT, 2021-2028 ($ MILLION)
  • 3. RECOVERY OF GLOBAL WOMEN HEALTH THERAPEUTICS MARKET, 2022-2028 (%)
  • 4. GLOBAL WOMEN HEALTH THERAPEUTICS MARKET SHARE BY TYPE, 2021 VS 2028 (%)
  • 5. GLOBAL WOMEN HEALTH THERAPEUTICS FOR INFECTIONMARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 6. GLOBAL WOMEN HEALTH THERAPEUTICS FOR PREGNANCYMARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 7. GLOBAL WOMEN HEALTH THERAPEUTICS FOR ONCOLOGYMARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 8. GLOBAL WOMEN HEALTH THERAPEUTICS MARKET SHARE BY END-USER, 2021 VS 2028 (%)
  • 9. GLOBAL WOMEN HEALTH THERAPEUTICS INHOSPITALS AND CLINICSMARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 10. GLOBAL WOMEN HEALTH THERAPEUTICS INAMBULATORY CENTERS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 11. GLOBAL WOMEN HEALTH THERAPEUTICS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 12. US WOMEN HEALTH THERAPEUTICS MARKET SIZE, 2021-2028 ($ MILLION)
  • 13. CANADA WOMEN HEALTH THERAPEUTICS MARKET SIZE, 2021-2028 ($ MILLION)
  • 14. UK WOMEN HEALTH THERAPEUTICS MARKET SIZE, 2021-2028 ($ MILLION)
  • 15. FRANCE WOMEN HEALTH THERAPEUTICS MARKET SIZE, 2021-2028 ($ MILLION)
  • 16. GERMANY WOMEN HEALTH THERAPEUTICS MARKET SIZE, 2021-2028 ($ MILLION)
  • 17. ITALY WOMEN HEALTH THERAPEUTICS MARKET SIZE, 2021-2028 ($ MILLION)
  • 18. SPAIN WOMEN HEALTH THERAPEUTICS MARKET SIZE, 2021-2028 ($ MILLION)
  • 19. REST OF EUROPE WOMEN HEALTH THERAPEUTICS MARKET SIZE, 2021-2028 ($ MILLION)
  • 20. INDIA WOMEN HEALTH THERAPEUTICS MARKET SIZE, 2021-2028 ($ MILLION)
  • 21. CHINA WOMEN HEALTH THERAPEUTICS MARKET SIZE, 2021-2028 ($ MILLION)
  • 22. JAPAN WOMEN HEALTH THERAPEUTICS MARKET SIZE, 2021-2028 ($ MILLION)
  • 23. SOUTH KOREA WOMEN HEALTH THERAPEUTICS MARKET SIZE, 2021-2028 ($ MILLION)
  • 24. REST OF ASIA-PACIFIC WOMEN HEALTH THERAPEUTICS MARKET SIZE, 2021-2028 ($ MILLION)
  • 25. REST OF THE WORLD WOMEN HEALTH THERAPEUTICS MARKET SIZE, 2021-2028 ($ MILLION)
目次
Product Code: MD-1229

Global Women Health Therapeutics Market Size, Share & Trends Analysis Report by Type (Infection, Pregnancy, and Oncology), and by End-User (Hospitals and Clinics and Ambulatory Centers) Forecast Period (2022-2028)

The global women health therapeutics market is anticipated to grow at a considerable CAGR of 5.3% during the forecast period. One of the core factors contributing to the growth of the market includes the growing demand forhealth diagnostics and therapeutics across the globe.This is due to the growing burden of breast cancer. Breast cancer is the most common cancer in women in the US. About 30% (or 1 in 3) of all new femalesare diagnosed with cancers each year. According to the American Cancer Society of the US, in 2022, about 287,850 new cases of invasive breast cancer were diagnosed in women. Furthermore, the rising several R&D and drug approval activities by key market players globally is another factor bolstering the market growth. For instance, inOctober 2021, the FDA approved a new drug for one type of breast cancer. The drug, named abemaciclib underthe brand name Verzenio, was approved for patients with the HR+, HER2-early breast cancer, which makes up 70% of all breast cancers.

The global women health therapeuticsmarket is segmented based on the type and end-user. Based on type, the market is classified into infection, pregnancy, and oncology. The oncology segment is further augmented into cervical cancer, uterine cancer, ovarian cancer, and vaginal &vular. Based on the end-user, the market is segmented into hospitals and clinics, and ambulatory centers. The above-mentioned segments can be customized as per the requirements.

Geographically the global women health therapeuticsmarket is segmented into North America, Europe, Asia Pacific, and the Rest of the World.North America is expected to hold a significant share in the global market due to the growing focus onwomen health and the increasing prevalence of chronic disorders such as breast and ovarian cancer.According to Globocan, in 2020, around 2.26 million new breast cancer cases were reported in females, accounting for around 11.7% of the total cancer cases. Severalproduct launches areanother key factor to drive the growth of the market across the region. For instance, in January 2021, Roche launched its CE-IVD-approved automated digital pathology algorithms, uPath HER2 (4B5) imageanalysis, and uPath HER2 Dual ISH image analysis for breast cancer.

The major companies serving the global women health therapeutics market include Novartis AG, Abbott Laboratories, Inc., Pfizer Inc., Eli Lilly and Co., Bayer AG, Merck KGaA, Novo Nordisk A/S, F. Hoffmann-La Roche Ltd, and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers andacquisitions, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in September 2021, Abbott acquired Walk Vascular LLC, a commercial-stage medical device firm with a minimally hostile mechanical aspiration thrombectomy system for the elimination of peripheral blood clots.

Research Methodology

The market study of the global women health therapeutics market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market into various segments, and derive the total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macroeconomic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include

  • Financial reports of companies involved in the market.
  • Whitepapers, research papers, and news blogs.
  • Company websites and their product catalog.

The report provides an in-depth analysis of the market size, and intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

1. Global Women Health Therapeutics Market Research and Analysis by Type.

2. Global Women Health Therapeutics Market Research and Analysis by End-User.

The Report Covers

  • Comprehensive research methodology of the global women health therapeutics market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global women health therapeuticsmarket.
  • Insights about market determinants that are stimulating the global women health therapeuticsmarket.
  • Detailed and extensive market segments with the regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

Category- Pharmaceuticals

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • Impact of COVID-19 on the Global Women Health Therapeutics Market
  • Recovery Scenario of Global Women Health Therapeutics Market
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
    • 3.1.1. Abbott Laboratories, Inc.
      • 3.1.1.1. Overview
      • 3.1.1.2. Financial Analysis
      • 3.1.1.3. SWOT Analysis
      • 3.1.1.4. Recent Developments
    • 3.1.2. Bayer AG
      • 3.1.2.1. Overview
      • 3.1.2.2. Financial Analysis
      • 3.1.2.3. SWOT Analysis
      • 3.1.2.4. Recent Developments
    • 3.1.3. Eli Lilly and Co.
      • 3.1.3.1. Overview
      • 3.1.3.2. Financial Analysis
      • 3.1.3.3. SWOT Analysis
      • 3.1.3.4. Recent Developments
    • 3.1.4. F. Hoffmann-La Roche LTD.
      • 3.1.4.1. Overview
      • 3.1.4.2. Financial Analysis
      • 3.1.4.3. SWOT Analysis
      • 3.1.4.4. Recent Developments
    • 3.1.5. Novartis AG
      • 3.1.5.1. Overview
      • 3.1.5.2. Financial Analysis
      • 3.1.5.3. SWOT Analysis
      • 3.1.5.4. Recent Developments
  • 3.2. Key Strategy Analysis
  • 3.3. Impact of COVID-19 on Key Players

4. Market Segmentation

  • 4.1. Global Women Health Therapeutics Market by Type
    • 4.1.1. Infection
    • 4.1.2. Pregnancy
    • 4.1.3. Oncology
      • 4.1.3.1. Cervical Cancer
      • 4.1.3.2. Uterine Cancer
      • 4.1.3.3. Ovarian Cancer
      • 4.1.3.4. Vaginal &Vular
  • 4.2. Global Women Health Therapeutics Market by End-User
    • 4.2.1. Hospital and Clinics
    • 4.2.2. Ambulatory Centers

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. US
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. South Korea
    • 5.3.5. Rest of Asia-Pacific
  • 5.4. Rest of the World

6. Company Profiles

  • 6.1. Airgas, Ltd.
  • 6.2. Allergan PLC
  • 6.3. Amgen Inc.
  • 6.4. Astellas Pharma Inc.
  • 6.5. Bayer AG
  • 6.6. Eli Lilly and Co
  • 6.7. ICON PLC
  • 6.8. Merck KGaA
  • 6.9. Mithra Pharmaceuticals S.A.
  • 6.10. Novo Nordisk A/S
  • 6.11. Pfizer Inc.
  • 6.12. Oasmia Pharmaceutical AB
  • 6.13. ObsEva SA
  • 6.14. Radius Health, Inc.
  • 6.15. Sanofi SA
  • 6.16. Takeda Pharmaceutical Co. Ltd.
  • 6.17. Teva Pharmaceuticals Industries Ltd.
  • 6.18. Tsumura & Co.Arkema S.A.